A Multicenter Prospective Real-world Study of Zanubrutinib Combined With Rituximab (ZR) in the First-line Treatment for Patients With Marginal Zone Lymphoma (MZL)
This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).
• Patients with CD20-positive marginal zone lymphoma diagnosed by histopathology
• First-line treatment with the combination regimen of zanubrutinib and rituximab
• No receiving systematic treatment before enrollment
• Having at least one measurable lesions. Measurable lesions were defined as: the longest diameter of lymph node lesions in CT cross-sectional images \> 1.5 cm, or the longest diameter of the extranodal lesion is greater than 1.0cm
• The patients voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.